COVID-19 vaccine developed by Pfizer and BioNTech is likely to protect against a more infectious variant of the virus, which was discovered in Britain and has spread around the world, according to results of further lab tests released on Wednesday.The encouraging results from an analysis of blood of participants in trials are based on more extensive analysis than those released by the US drugmaker last week.Last week, Pfizer said a similar laboratory study showed the vaccine was effective against one key mutation, called N501Y, found in both of the highly transmissible new variants spreading in Britain and South Africa.The latest study, posted on bioRxiv.org but not yet peer reviewed, was conducted on a synthetic virus with 10 mutations.